Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2020 | Story André Damons | Photo Supplied
Read More Bianca Vermeulen
Bianca Vermeulen started her journey to become a doctor this year after being accepted by the University of the Free State (UFS) to study medicine. She had previously applied 32 times in eight years to study medicine.

A first-year medical student from the University of Free State (UFS) is finally on her way to realise her childhood dream of becoming a doctor after having been rejected 32 times in eight years to study medicine.

Bianca Vermeulen, who started the MBChB programme in 2020, said she applied 32 times in eight years and got rejected every time. As a qualified Critical Care Clinical Technologist who worked for the Free State Department of Health, the daily interaction with her patients and colleagues inspired her to keep her dream alive.

“My childhood dream (of becoming a doctor) did not fade. Dreams do not have expiry dates. During my time in the clinical setting, I learnt some important life lessons. Experience is most definitely what I got when I did not get what I wanted,” said Vermeulen.

According to her, working in a clinical setting fueled her passion. Said Bianca: “I woke up to an alarm clock of opportunity. At the end of the day I can go home with a feeling of satisfaction. I could not have done it without the support of my colleagues and friends. Then it all becomes worth it.”

Finally, a yes to study medicine

Vermeulen said she was at work when she received an e-mail on 3 October 2019 from the UFS application office. She initially ignored the e-mail thinking they would resend one of their earlier rejection letters. After ‘accidentally’ opening the letter, she could not believe her eyes.

“For a moment I was in denial. I had to read the letter a few times to ensure my eyes were not bewitching me. I had to show a friend to ensure that I had read and understood the letter. Then the reality came as an overwhelming mixture of emotions.”

Studying medicine during a pandemic

Vermeulen , who has a passion for neonatal and paediatric intensive care and would like to specialise in paediatrics and child health care after her undergraduate studies, said she welcomes the change that COVID-19 brought to the academic table.

“Daily routine changed overnight for all people and all stared uncertainty in the face. Students had to adapt to a blended learning approach (which also had its own challenges), but as time progressed, we learnt the new ropes.

“I truly hope that we all take the COVID lessons to heart. In the medical sector, no one is a greater ‘hero’ than another. The sector needs various role players and I hope that people realise the importance of nurses, hospital cleaners, administrative staff and all allied health workers. Without these people, the medical sector cannot function. We all need one another.

“With that being said, I hope people realise that we need a functional system so that we can work with each other and not against a system,” said Vermeulen.

Working with various healthcare workers, she has seen the effects of burnout and experienced the best (and worst) of both worlds but is still happy with her choice to study medicine.

It only takes one successful application

“As [US educator] Randy Pausch said: ‘The brick walls are there for a reason. The brick walls are not there to keep us out. The brick walls are there to give us a chance to show how badly we want something.’ I take this to heart,” Vermeulen said.

“You might have received ample unsuccessful applications, but it will only take one successful application to commence with your dream. If it is truly something you want to do, never give up on your dreams. Always work hard and take to heart what the Lord has done for you!”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept